Related Experiment Video
Updated: May 4, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.8K
The pharmacogenomics of statins
Ingrid C Gelissen1, Andrew J McLachlan2
1Faculty of Pharmacy, University of Sydney, NSW, Australia.
Pharmacological Research
|December 25, 2013
Summary
Pharmacogenomics offers insights into how gene variants impact statin drug effectiveness and side effects. Understanding these genetic factors can help predict individual responses to cholesterol-lowering therapy.
Area of Science:
- Pharmacology
- Genetics
- Cardiovascular Medicine
Background:
- Statins are widely used cholesterol-lowering drugs that reduce cardiovascular risk.
- Adverse effects of statins can increase with patient age and polypharmacy.
- Predicting individual patient response to statin therapy remains a clinical challenge.
Purpose of the Study:
- To review candidate genes influencing statin pharmacokinetics and pharmacodynamics.
- To highlight the role of pharmacogenomics in statin efficacy and safety.
- To discuss genetic factors affecting cholesterol homeostasis and statin response.
Main Methods:
- Literature review of pharmacogenomic studies on statins.
- Analysis of candidate genes affecting statin absorption, metabolism, and action.
- Examination of genetic variants linked to statin efficacy and adverse events.
Main Results:
- Specific gene variants impact statin efficacy and safety profiles.
- Genes involved in statin transport (import/efflux) are associated with increased side effect risk.
- Pharmacogenomic research continues to uncover new genetic regulators of cholesterol metabolism and statin response.
Conclusions:
- Pharmacogenomics is crucial for personalizing statin therapy.
- Genetic profiling can help optimize statin treatment and minimize adverse effects.
- Further research into gene-drug interactions will refine statin prescribing practices.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:27Pharmacogenetics of Drug Metabolism: Overview
194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
01:29Pharmacogenetics and Pharmacogenomics: Overview
253
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
253
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
01:27Principles of Pharmacogenetics: Types of Genetic Variants
138
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
338
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
338